Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactive agents, and their use varies geographically. Large trials are needed to assess safety and effectiveness. For ...
Add Yahoo as a preferred source to see more of our stories on Google. Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 ...
For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...
The FDA is weighing the regulatory fate of Insmed’s DPP1 inhibitor brensocatib for bronchiectasis. An approval for the oral small-molecule protease inhibitor would provide a much-needed targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results